Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05988697 |
Recruitment Status :
Not yet recruiting
First Posted : August 14, 2023
Last Update Posted : October 12, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
NSCLC BRAF V600E Mutation Advanced Cancer Stage IIIB NSCLC Stage IV NSCLC | Drug: Combind asprin with Trametinib and Dabrafenib |
Study Type : | Observational |
Estimated Enrollment : | 36 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | An Observational Phase II Study to Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib in Advanced Non-small Cell Lung Cancer Patients With BRAF V600E Mutation |
Estimated Study Start Date : | November 1, 2023 |
Estimated Primary Completion Date : | September 1, 2026 |
Estimated Study Completion Date : | April 1, 2027 |
Group/Cohort | Intervention/treatment |
---|---|
Observation group
Primary IIIB-IV BRAF V600E mutated advanced non-small cell lung cancer in a population of patients with advanced lung cancer proposed to be treated with Trametinib, Dabrafenib and Asprin
|
Drug: Combind asprin with Trametinib and Dabrafenib
Treatment drug: Dabrafenib 150 mg BID, Trametinib 2 mg QD, Aspirin 100 mg/tablet, 1 tablet/time, QD |
- PFS [ Time Frame: 3 years ]Progression-free survival (PFS) was calculated in 36 patients treated with aspirin combined with Dabrafenib and Trametinib
- Proportion of patients with fever [ Time Frame: C ]Refers to the proportion of patients with fever from the beginning of treatment to the end of follow-up.
- OS [ Time Frame: 3 years ]3 year Overall Survival (OS) was calculated in 36 patients treated with aspirin combined with Dabrafenib and Trametinib
- ORR [ Time Frame: 3 years ]The Objective Response Rate (ORR) was calculated in 36 patients treated with aspirin combined with Dabrafenib and Trametinib. ORR will be analyzed using tests, and logistic regression methods will be used to explore other factors that influence the outcome.
- DCR [ Time Frame: 3 years ]The Disease Control Rate (DCR) was calculated in 36 patients treated with aspirin combined with Dabrafenib and Trametinib. DCR will be analyzed using tests, and logistic regression methods will be used to explore other factors that influence the outcome.
- Risk of coronary events [ Time Frame: 3 years ]Risk of coronary events was calculated in 36 patients treated with aspirin combined with Dabrafenib and TrametinibTrametinib
- Effectiveness evaluation/efficacy analysis [ Time Frame: 3 years ]Univariate analysis of the relationship between lung cancer and treatment regimens: DFS and OS were used to compare whether there was a statistical difference (P-value less than or equal to 0.05) in the overall survival curve between the experimental and control groups by log-rank test; Multifactor analysis: PFS and OS will use a COX-proportional hazard model to estimate the hazards ratio and explore other factors that influence efficacy.
- Security assessment [ Time Frame: 3 years ]Security analysis data sets will be used for analysis. descriptive statistics, adverse events (AE), laboratory test results (blood biochemistry, liver and kidney function, coagulation and stool routine, etc.) and important vital signs (such as blood pressure) were mainly used to summarize and analyze the list.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Inoperable stage IIIB-IV patients with non-small cell lung cancer;
- BRAF V600E mutation;
- Dabrafenib and Trametinib are planned for treatment, and the survival period is expected to be more than 3 months;
- ECOG PS 0/1;
- The diameter of the primary lesion should be at least 1cm;
- Previous or current aspirin treatment was allowed
Exclusion Criteria:
- The patient is currently receiving other anticoagulant therapy;
- The patient was previously treated with systemic anti-NSCLC;
- The patient had other positive driver mutations, including EGFR, ALK, ROS1, MET14, RET, etc.
- The patient had contraindications for dalafenib or trametinib and aspirin use;
- Patients who refused follow-up visits;
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05988697
Contact: He Yong, MD | 86-23-68757791 | heyong@dphospital.tmmu.edu.cn |
Responsible Party: | Yong He, Director of Department of Respiratory Diseases, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University |
ClinicalTrials.gov Identifier: | NCT05988697 |
Other Study ID Numbers: |
DATE |
First Posted: | August 14, 2023 Key Record Dates |
Last Update Posted: | October 12, 2023 |
Last Verified: | October 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
NSCLC Asprin Dabrafenib |
Trametinib PFS BRAF V600E mutation |
Carcinoma, Non-Small-Cell Lung Carcinoma, Bronchogenic Bronchial Neoplasms Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms |
Lung Diseases Respiratory Tract Diseases Trametinib Dabrafenib Antineoplastic Agents Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |